AIM: Impaired heart rate (HR) response to exercise is associated with increased cardiovascular morbidity and mortality. We analyzed whether common variants (rs5443/C825T and rs5442/G814A) in the G-protein β3 subunit (GNB3) gene modulate interindividual variation in β-blocker responses with respect to HR. MATERIALS & METHODS: Among 1614 subjects (347 current β-blocker users) of a population-based study, HR during symptom-limited exercise testing was analyzed by multilevel linear regression models adjusted for potential confounders. RESULTS: In β-blocker users, but not in nonusers, HR was attenuated in rs5443 T allele carriers (TC/TT vs CC) with lower adjusted HR over the entire exercise period from rest to peak workload (3.5 bpm; 95% CI: 1.1-5.8; p < 0.01), and during recovery (4.2 bpm; 95% CI: 0.6-7.8; p = 0.02). The genotype-related HR reducing effect at peak exercise varied by up to 7.5 bpm (CC vs TT), more than a third (35.9%) of the total β-blocker effect (20.9 bpm). By contrast, rs5442 had no impact on any HR-related parameter. CONCLUSION: In this population-based sample, a common GNB3 polymorphism (C825T) was significantly related with response to β-blocker therapy with respect to HR during exercise and HR recovery, respectively. Further prospective studies are needed to confirm these associations and to examine their potential clinical relevance.
AIM: Impaired heart rate (HR) response to exercise is associated with increased cardiovascular morbidity and mortality. We analyzed whether common variants (rs5443/C825T and rs5442/G814A) in the G-protein β3 subunit (GNB3) gene modulate interindividual variation in β-blocker responses with respect to HR. MATERIALS & METHODS: Among 1614 subjects (347 current β-blocker users) of a population-based study, HR during symptom-limited exercise testing was analyzed by multilevel linear regression models adjusted for potential confounders. RESULTS: In β-blocker users, but not in nonusers, HR was attenuated in rs5443 T allele carriers (TC/TT vs CC) with lower adjusted HR over the entire exercise period from rest to peak workload (3.5 bpm; 95% CI: 1.1-5.8; p < 0.01), and during recovery (4.2 bpm; 95% CI: 0.6-7.8; p = 0.02). The genotype-related HR reducing effect at peak exercise varied by up to 7.5 bpm (CC vs TT), more than a third (35.9%) of the total β-blocker effect (20.9 bpm). By contrast, rs5442 had no impact on any HR-related parameter. CONCLUSION: In this population-based sample, a common GNB3 polymorphism (C825T) was significantly related with response to β-blocker therapy with respect to HR during exercise and HR recovery, respectively. Further prospective studies are needed to confirm these associations and to examine their potential clinical relevance.
Authors: Henry Völzke; Dietrich Alte; Carsten Oliver Schmidt; Dörte Radke; Roberto Lorbeer; Nele Friedrich; Nicole Aumann; Katharina Lau; Michael Piontek; Gabriele Born; Christoph Havemann; Till Ittermann; Sabine Schipf; Robin Haring; Sebastian E Baumeister; Henri Wallaschofski; Matthias Nauck; Stephanie Frick; Andreas Arnold; Michael Jünger; Julia Mayerle; Matthias Kraft; Markus M Lerch; Marcus Dörr; Thorsten Reffelmann; Klaus Empen; Stephan B Felix; Anne Obst; Beate Koch; Sven Gläser; Ralf Ewert; Ingo Fietze; Thomas Penzel; Martina Dören; Wolfgang Rathmann; Johannes Haerting; Mario Hannemann; Jürgen Röpcke; Ulf Schminke; Clemens Jürgens; Frank Tost; Rainer Rettig; Jan A Kors; Saskia Ungerer; Katrin Hegenscheid; Jens-Peter Kühn; Julia Kühn; Norbert Hosten; Ralf Puls; Jörg Henke; Oliver Gloger; Alexander Teumer; Georg Homuth; Uwe Völker; Christian Schwahn; Birte Holtfreter; Ines Polzer; Thomas Kohlmann; Hans J Grabe; Dieter Rosskopf; Heyo K Kroemer; Thomas Kocher; Reiner Biffar; Ulrich John; Wolfgang Hoffmann Journal: Int J Epidemiol Date: 2010-02-18 Impact factor: 7.196
Authors: Tuomo Rankinen; Treva Rice; Arthur S Leon; James S Skinner; Jack H Wilmore; D C Rao; Claude Bouchard Journal: Physiol Genomics Date: 2002-02-28 Impact factor: 3.107
Authors: Jens Nürnberger; Sandra Dammer; Anna Mitchell; Winfried Siffert; René R Wenzel; Mario Gössl; Thomas Philipp; Martin C Michel; Rafael F Schäfers Journal: Clin Pharmacol Ther Date: 2003-07 Impact factor: 6.875
Authors: John Wikstrand; Ake Hjalmarson; Finn Waagstein; Björn Fagerberg; Sidney Goldstein; John Kjekshus; Hans Wedel Journal: J Am Coll Cardiol Date: 2002-08-07 Impact factor: 24.094
Authors: Amber E Johnson; Karen Hanley-Yanez; Clyde W Yancy; Anne L Taylor; Arthur M Feldman; Dennis M McNamara Journal: J Card Fail Date: 2019-04-09 Impact factor: 5.712
Authors: Mohamed H Shahin; Nihal El Rouby; Daniela J Conrado; Daniel Gonzalez; Yan Gong; Maximilian T Lobmeyer; Amber L Beitelshees; Eric Boerwinkle; John G Gums; Arlene Chapman; Stephen T Turner; Carl J Pepine; Rhonda M Cooper-DeHoff; Julie A Johnson Journal: J Clin Pharmacol Date: 2019-05-14 Impact factor: 3.126